Coronavirus isn’t the only thing on FDA’s mind
Drugs are still being approved and reports are still churning out, all while the FDA battles the COVID-19 outbreak.
Drugs are still being approved and reports are still churning out, all while the FDA battles the COVID-19 outbreak.
The FDA and FTC want to ensure companies don’t use anticompetitive practices to squash the biosimilar market.
A recent IQVIA report breaks down global medicine spending and eyes what lies ahead.
A report from the IQVIA Institute for Human Data Science identified areas to watch through 2023.
Biosimilars have only been in the market for three years, but they have struggled to compete with their branded equivalents.
Although if approved, it’s not likely to launch in the U.S. for quite some time.
Maker of Botox biosimilar Evolus files IPO; pharma execs expect major acquisitions in 2018; J&J and Bayer win Xarelto reversal verdict
Tax bill could lead pharma to move overseas; global pharma sales increased 45% in nine years; FDA OKs first gene therapy for rare retinal disease
WebMD reportedly lays off 10% of workforce; Roche blocks Herceptin biosimilar with patent suit; insurers cover Collegium’s Xtampza over Purdue’s OxyContin
FDA approves AstraZeneca asthma drug; Senate tax reform bill would repeal Obamacare mandate; J&J drops Remicade biosimilar lawsuit